Alliance Global says clinical hold lift ‘de-risking’ event for vTv Therapeutics

After the FDA lifted the clinical hold on vTv Therapeutics (VTVT)’ CATT1 trial, the firm called it a “de-risking” event for shares of the company. Alliance Global noted that the company plans to submit a protocol amendment for a six-month study protocol for the CATT1 study for cadisegliatin, potentially cutting in half the expected 12-month protocol it had previously reported. The firm added this news is a “significant positive” for vTv Therapeutics. Alliance Global Partners analyst James Molloy reiterates a Buy rating and $35 price target on vTv Therapeutics shares.